4-[4-(2-Phenylethyl)-2-propylpyrazol-3-yl]piperidine | 301219-85-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-[4-(2-Phenylethyl)-2-propylpyrazol-3-yl]piperidine
• CAS: 301219-85-2
• 化学式: C₁₉H₂₇N₃
• 分子量: 297.443
• InChiKey: CMIZWURZDKVVLE-UHFFFAOYSA-N

物化性质

• 沸点：
  430.7±45.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-[4-(2-Phenylethyl)-2-propylpyrazol-3-yl]piperidine 在 palladium on activated charcoal 氢气 、 三乙酰氧基硼氢化钠 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 生成 Cyclohexyl-{3-[4-(4-phenethyl-2-propyl-2H-pyrazol-3-yl)-piperidin-1-ylmethyl]-4-phenyl-pyrrolidin-1-yl}-acetic acid
  参考文献：
  名称：

  Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains

  摘要：

  Replacement of the flexible connecting chains between the piperidine moiety and an aromatic group in previous CCR5 antagonists with heterocycles, such as pyrazole and isoxazole, provided potent CCR5 antagonists with excellent anti-HIV-1 activity in vitro. SAR studies revealed optimal placement of an unsubstituted nitrogen atom in the heterocycle to be meta to the bond connected to the 4-position of piperidine. Truncation of a benzyl group to a phenyl group afforded compounds with dramatically improved oral bioavailability, albeit with reduced activity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.004
• 作为产物：
  描述：

  4-苯基-1-丁基溴 在 palladium dihydroxide chromium(VI) oxide 、 硫酸 、 硼烷 、 potassium tert-butylate 、 ammonium formate 、 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 生成 4-[4-(2-Phenylethyl)-2-propylpyrazol-3-yl]piperidine
  参考文献：
  名称：

  Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains

  摘要：

  Replacement of the flexible connecting chains between the piperidine moiety and an aromatic group in previous CCR5 antagonists with heterocycles, such as pyrazole and isoxazole, provided potent CCR5 antagonists with excellent anti-HIV-1 activity in vitro. SAR studies revealed optimal placement of an unsubstituted nitrogen atom in the heterocycle to be meta to the bond connected to the 4-position of piperidine. Truncation of a benzyl group to a phenyl group afforded compounds with dramatically improved oral bioavailability, albeit with reduced activity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.004

文献信息

• [EN] PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] PYRROLIDINES MODULATEURS DE L'ACTIVITE DU RECEPTEUR DE CHIMIOKINE
  申请人：MERCK & CO INC

  公开号：WO2000059502A1

  公开（公告）日：2000-10-12

  The present invention is directed to pyrrolidine compounds of formula (I) (wherein R?1, R2, R3, R4, R5, R6, R14¿ and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

  本发明涉及式(I)的吡咯烷化合物（其中R1，R2，R3，R4，R5，R6，R14和n在此定义），其作为趋化因子受体活性调节剂具有用途。特别地，这些化合物作为趋化因子受体CCR-5和/或CCR-3的调节剂具有用途。
• EP1171122A4
  申请人：——

  公开号：EP1171122A4

  公开（公告）日：2002-05-29
• PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Merck & Co., Inc.

  公开号：EP1171122A1

  公开（公告）日：2002-01-16
• US6248755B1
  申请人：——

  公开号：US6248755B1

  公开（公告）日：2001-06-19
• Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains
  作者：Dong-Ming Shen、Min Shu、Sander G. Mills、Kevin T. Chapman、Lorraine Malkowitz、Martin S. Springer、Sandra L. Gould、Julie A. DeMartino、Salvatore J. Siciliano、Gloria Y. Kwei、Anthony Carella、Gwen Carver、Karen Holmes、William A. Schleif、Renee Danzeisen、Daria Hazuda、Joseph Kessler、Janet Lineberger、Michael D. Miller、Emilio A. Emini

  DOI：10.1016/j.bmcl.2003.12.004

  日期：2004.2

  Replacement of the flexible connecting chains between the piperidine moiety and an aromatic group in previous CCR5 antagonists with heterocycles, such as pyrazole and isoxazole, provided potent CCR5 antagonists with excellent anti-HIV-1 activity in vitro. SAR studies revealed optimal placement of an unsubstituted nitrogen atom in the heterocycle to be meta to the bond connected to the 4-position of piperidine. Truncation of a benzyl group to a phenyl group afforded compounds with dramatically improved oral bioavailability, albeit with reduced activity. (C) 2004 Elsevier Ltd. All rights reserved.